# A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone

Study · id `cardio:ct-nct01555164` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01555164](<https://clinicaltrials.gov/study/NCT01555164>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01555164

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 442 participants.

## Technical summary

Registry record NCT01555164. Randomized; double masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2013-09 (actual). Results posted on 2014-09-23.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 442 participants (enrolled count; ClinicalTrials.gov record NCT01555164, source copy `cardio:ctgov-nct01555164-2014-09-23`, retrieved 2026-10-26)
- Start date: 2012-06 (registry gives no type) (ClinicalTrials.gov record NCT01555164, source copy `cardio:ctgov-nct01555164-2014-09-23`, retrieved 2026-10-26)
- Primary completion: 2013-09 (actual) (ClinicalTrials.gov record NCT01555164, source copy `cardio:ctgov-nct01555164-2014-09-23`, retrieved 2026-10-26)
- Completion: 2013-10 (actual) (ClinicalTrials.gov record NCT01555164, source copy `cardio:ctgov-nct01555164-2014-09-23`, retrieved 2026-10-26)
- Results first posted: 2014-09-23 (ClinicalTrials.gov record NCT01555164, source copy `cardio:ctgov-nct01555164-2014-09-23`, retrieved 2026-10-26)
- Countries: United States; Canada; Czechia; Hungary; India; Israel; Mexico; Poland; Russia; South Africa; Ukraine (ClinicalTrials.gov record NCT01555164, source copy `cardio:ctgov-nct01555164-2014-09-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01555164-2014-09-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Ranolazine
- Intervention (Drug): Placebo to match ranolazine
- Intervention (Drug): Metformin
- Intervention (Drug): Placebo to match metformin
- Intervention (Behavioral): Diet
- Intervention (Behavioral): Exercise
- Lead sponsor: Gilead Sciences
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Gilead Sciences (`cardio:org-gilead-sciences`)

## Provenance

Content hash: 1ab49d023262cce53f8787e812a28983870cdd3c1162afd656bb5746b04465ca
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
